Adrenal Gland Diseases

HHS Proposes Loosening Testosterone Therapy Warning Requirements

The HHS has proposed changes to testosterone therapy warnings, potentially reducing emphasis on cardiovascular risk. This may alter prescribing practices for hypogonadism.

Classic CAH: New Approaches to Glucocorticoid Dosing

Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.

Low Alkaline Phosphatase: Recognizing Clinical Consequences

Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.

XLH Adults: Osteomalacia Persists Despite Conventional Therapy

Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.

Desmopressin Dosing Refined for Central Diabetes Insipidus

New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.

Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives

New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.

Hypercortisolism: Emerging Diagnostic and Management Insights

New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.

Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps

Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.

Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data

New data from endo 2026 highlights patient-reported improvements in Cushing's syndrome symptoms with Korlym® (mifepristone) treatment.

Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome

A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.